AstraZeneca explores $400B combination with BMS
AstraZeneca has held talks with Bristol Myers Squibb over a potential combination that would create a pharmaceutical group worth nearly $400 billion (€348 billion), the Financial Times reported.
Why it matters: The transaction would rank among the largest pharmaceutical deals ever and create the world’s fourth-largest drugmaker by market value. It would also represent a sharp strategic turn for AstraZeneca, which has spent the past decade building its pipeline through targeted acquisitions and licensing deals rather than another industry-defining merger.
By the numbers: AstraZeneca was valued at about £196 billion (€230 billion) before the report, compared with $133 billion (€116 billion) for BMS. AstraZeneca shares fell to approximately 7% in early London trading this morning, suggesting investors are unconvinced by the prospect of combining two companies with markedly different growth profiles.
The strategic logic: BMS would give AstraZeneca even greater scale in the U.S., which already generates nearly half of the UK drugmaker’s revenue. It would also add approved products and clinical programs in oncology, hematology, cardiovascular disease, immunology and neuroscience.
- BMS is not standing still. Its newer medicines generated $7.6 billion (€6.6 billion) in the second quarter, up 15%, driven by products including Reblozyl, Camzyos, Breyanzi and Opdualag. The company also raised its 2026 revenue forecast to between $49 billion and $50 billion (around €43 billion).
Yes, but: BMS is preparing for major losses of exclusivity. Generic competition has already eroded sales of Revlimid and other older products, while the company estimates that U.S. market exclusivity for both Eliquis and Opdivo could end in 2028, according to its 2025 annual report. That creates a difficult proposition for AstraZeneca: BMS offers substantial revenue and a growing portfolio, but also brings a patent cliff that its newer medicines still need to offset.
The antitrust problem: Both companies have extensive cancer portfolios. BMS’ PD-1 inhibitor Opdivo and AstraZeneca’s PD-L1 drug Imfinzi compete in several tumor types, including non-small cell lung cancer. Regulators could therefore demand significant divestments, reducing some of the oncology scale that would ostensibly make the combination attractive.
Between the lines: The talks come shortly after AstraZeneca reaffirmed its goal of reaching $80 billion (€70 billion) in annual revenue by 2030. CEO Pascal Soriot said last week that the company did not “need M&A to deliver” that target. A deal would also intensify UK concerns about AstraZeneca shifting its center of gravity toward the U.S., where it has expanded its stock market presence and committed to invest $50 billion by 2030.
What’s next: According to the Financial Times report, neither company has confirmed the discussions, and the structure of any transaction remains unclear. The talks could produce an agreement soon, but could equally be delayed or abandoned.
The bottom line: BMS could give AstraZeneca more U.S. scale and a broader portfolio. The harder question is whether those benefits justify absorbing its patent exposure, oncology overlaps and the disruption of one of pharma’s largest integrations.
